Adam Feuerstein

This week in biotechnology: Adam Feuerstein’s subscriber-only newsletter digs into Skye Bioscience and Gritstone Bio.

Among other readouts, Sage Therapeutics will report study results on two drugs and Pfizer is expected to announce results from a gene therapy study.

This week in biotechnology: Adam Feuerstein’s subscriber-only newsletter digs into Viking Therapeutics and PDS Biotech.

Adam Feuerstein has covered the intersection of Wall Street and biotechnology for decades. STAT subscribers can see his insightful analysis every Thursday.

This week: A preview of Intra-Cellular Therapies’ depression drug study, and a couple of liver-disease physician perspectives on Rezdiffra.

For years, I’ve believed — and declared publicly — that Geron’s effort to develop imetelstat would end in disappointment.

The company has developed the IgG-lowering antibody Vyvgart to treat patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

Rezdiffra, a pill developed by Madrigal Pharmaceuticals, targets a protein directly in the liver that reduces liver fat, inflammation, and scarring.

Resmetirom, a pill developed by Madrigal Pharmaceuticals, targets a protein in the liver that reduces liver fat, inflammation, and scarring.

Currently approved to treat hallucinations associated with Parkinson’s disease psychosis, the drug failed to do better than placebo in a late-stage clinical trial.

The failure of Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, raises tough questions for the patients, disease advocates, and the FDA.

The results of the trial now have the company considering a voluntary withdrawal of the approved medicine from the market.

This week a deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences.

Patients treated longer with the drug, efruxifermin, saw sustained reductions in the liver scarring that characterizes MASH.

This year has seen at least 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds).

After a late change to the design of a Phase 3 study, Annovis Bio’s clinical trial seems even less likely to succeed.

Adam Feuerstein games out upcoming results on the supplement TUDCA for ALS patients, and chats with CRISPR Therapeutics’ CEO.

The company plans to submit sebetralstat for FDA approval to relieve symptoms from hereditary angioedema, a disease that can be fatal.

Adam Feuerstein previews the expected readout from Gritstone Bio’s neoantigen cancer vaccine study, and discusses the Novartis-MorphoSys deal.

The Swiss drug giant will be happy to pay a small breakup fee to MorphoSys to avoid owning a drug that regulators will turn away.